SEC Filing Summary: Spherix Incorporated (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Spherix Incorporated (SPEX) on May 29, 2019, covering events occurring on May 29 and May 30, 2019. The filing details a private placement of equity securities and an amendment to a pending asset purchase agreement. Note: The request metadata referenced "Dominari Holdings Inc.," but the filing text explicitly identifies the registrant as Spherix Incorporated.
Key Financial Metrics and Transaction Details
- Capital Raised: The Company sold 221,000 shares of Common Stock and pre-funded warrants for 86,692 shares.
- Pricing: Common Stock was sold at $2.60 per share; Warrants were sold at $2.5999 per warrant.
- Proceeds: Aggregate gross proceeds were approximately $799,991. Net proceeds were also approximately $799,991.
- Use of Proceeds: Funds are designated for working capital purposes.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, or debt metrics. It is a transactional report, not a periodic financial statement.
Material Changes and Agreements
- Securities Purchase Agreement: Entered into on May 29, 2019, with a single accredited investor. The transaction closed on May 31, 2019. Warrants are immediately exercisable at $0.0001 per share, subject to a 9.99% beneficial ownership limitation.
- Asset Purchase Agreement Amendment: On May 30, 2019, the Company amended its agreement with CBM BioPharma, Inc. to include a termination fee.
- Termination Fee: If the asset purchase is terminated by CBM due to a material breach by the Company (uncured within 20 days) or if stockholders fail to approve the equity consideration by December 31, 2019, the Company must issue 250,000 shares of Common Stock to CBM.
Outlook, Risks, and Contingencies
- Contingency: The asset purchase with CBM BioPharma is contingent upon stockholder approval of the equity portion of the consideration.
- Risk: Failure to obtain stockholder approval or a material breach by the Company could trigger the issuance of 250,000 shares as a termination fee.
- Regulatory Status: The securities were offered pursuant to an effective shelf registration statement (Form S-3) filed in January 2018.
- Management Commentary: The filing does not contain forward-looking guidance or management commentary beyond the description of the agreements.
Key Facts for Investor Verification
- Verify the closing date of the transaction (May 31, 2019) and the actual receipt of net proceeds.
- Confirm the status of the stockholder vote required to approve the equity consideration for the CBM BioPharma asset purchase.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Warrant (Exhibit 4.1) for specific covenants and exercise restrictions.
- Assess the dilution impact of the 221,000 new shares and the potential 86,692 warrant shares, as well as the potential 250,000 termination fee shares.